[en] In a previous work, we predicted and demonstrated that the 29-42-residue fragment
of beta-amyloid peptide (Abeta peptide) has in vitro capacities close to those of
the tilted fragment of viral fusion proteins. We further demonstrated that
apolipoprotein E2 and E3 but not apolipoprotein E4 can decrease the fusogenic
activity of Abeta(29-42) via a direct interaction. Therefore, we suggested that
this fragment is implicated in the neurotoxicity of Abeta and in the protective
effects of apolipoprotein E in Alzheimer's disease. Because structurally related
apolipoproteins do not interact with the Abeta C-terminal domain but inhibit
viral fusion, we suggested that interactions existing between fusogenic peptides
and apolipoproteins are selective and responsible for the inhibition of fusion.
In this study, we simulated interactions of all amphipathic helices of
apolipoproteins E and A-I with Abeta and simian immunodeficiency virus (SIV)
fusogenic fragments by molecular modeling. We further calculated
cross-interactions that do not inhibit fusion in vitro. The results suggest that
interactions of hydrophobic residues are the major event to inhibit the fusogenic
capacities of Abeta(29-42) and SIV peptides. Selectivity of those interactions is
due to the steric complementarity between bulky hydrophobic residues in the
fusogenic fragments and hydrophobic residues in the apolipoprotein C-terminal
amphipathic helices.
Aggerbeck L. P., Wetterau J. R., Weisgraber K. H., Wu C. S., and Lindgren F. T. (1988) Human apolipoprotein E3 in aqueous solution. II. Properties of the amino- and carboxyl-terminal domains. J. Biol. Chem. 263, 6249-6258.
Benhabiles N., Gallet X., Thomas-Soumarmon A., and Brasseur R. (1998) A descriptive analysis of populations of three-dimensional structures calculated from primary sequences of proteins by OSIRIS. J. Comput. Biol. 5, 351-366.
Brasseur R. (1990) Molecular Description of Biological Membrane Components by Computer-Aided Conformational Analysis. CRC Press, Boca Raton, Florida.
Brasseur R. (1991) Differentiation of lipid-associating helices by use of three-dimensional molecular hydrophobicity potential calculations. J. Biol. Chem. 266, 16120-16127.
Brasseur R. (1995) Simulating the folding of small proteins by use of the local minimum energy and the free solvation energy yields native-like structures. J. Mol. Graphics 13, 312-322.
Brasseur R., Killian J. A., De Kruijff B., and Ruysschaert J. M. (1987) Conformational analysis of gramicidin - gramicidin interactions at the air/water interface suggests that gramicidin aggregates into tube-like structures similar as found in the gramicidin-induced hexagonal HII phase. Biochim. Biophys. Acta 903, 11-17.
Brasseur R., Lins L., Vanloo B., Ruysschaert J. M., and Rosseneu M. (1992) Molecular modeling of the amphipathic helices of the plasma apolipoproteins. Proteins Struct. Funct. Genet. 13, 246-257.
Brasseur R., Pillot T., Lins L., Vandekerckhove J., and Rosseneu M. (1997) Peptides in membranes: tipping the balance of membrane stability. Trends Biochem. Sci. 22, 167-171.
Busciglio J., Gabuzda D. H., Matsudaira P., and Yankner B. A. (1993) Generation of beta-amyloid in the secretory pathway in neuronal and nonneuronal cells. Proc. Natl. Acad. Sci. USA 90, 2092-2096.
Cai X. D., Golde T. E., and Younkin S. G. (1993) Release of excess amyloid beta protein from a mutant amyloid beta protein precursor. Science 259, 514-516.
Chang D. K., Cheng S. F., and Chien W. J. (1997) The amino-terminal fusion domain peptide of human immunodeficiency virus type 1 gp41 inserts into the sodium dodecyl sulfate micelle primarily as a helix with a conserved glycine at the micelle - water interface. J. Virol. 71, 6593-6602.
Coles M., Bicknell W., Walson A. A., Fairlie D. P., and Craik D. J. (1998) Solution structure of amyloid beta-peptide(1-40) in a water - micelle environment. Is the membrane-spanning domain where we think it is? Biochemistry 37, 11064-11077.
Corder E. H., Saunders A. M., Strittmatter W. J., Schmechel D. E., Gaskell P. C., Small G. W., Roses A. D., Haines J. L., and Pericak-Vance M. A. (1993) Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 261, 921-923.
Currie J. R., Wisniewski H. M., Chauhan A., Brockerhoff H., and Wegiel J. (1990) Alzheimer amyloid β-ptotein: cell of origin and possible fusogenic and membranolytic properties, in Regulation of Gene Expression in the Nervous System, pp. 343-354. Wiley -Liss, New York.
De Pauw M., Vanloo B., Weisgraber K., and Rosseneu M. (1995) Comparison of lipid-binding and lecithin:cholesterol acyltransferase activation of the amino- and carboxyl-terminal domains of human apolipoprotein E3. Biochemistry 34, 10953-10966.
De Pauw M., Vanloo B., Dergunov A. D., Devreese A. M., Baert J., Brasseur R., and Rosseneu M. (1997) Composition and structural and functional properties of discoidal and spherical phospholipid-apoE3 complexes. Biochemistry 34, 251-263.
Dong L. M., Parkin S., Trakhanov S. D., Rupp B., Simmons T., Arnold K. S., Newhouse Y. M., Innerarity T. L., and Weisgraber K. H. (1996) Novel mechanism for defective receptor binding of apolipoprotein E2 in type III hyperlipoproteinemia. Nat. Struct. Biol. 3, 718-722.
Evans K. C., Berger E. P., Cho C. G., Weisgraber K. H., and Lansbury P. T. J. (1995) Apolipoprotein E is a kinetic but not a thermodynamic inhibitor of amyloid formation: implications for the pathogenesis and treatment of Alzheimer disease. Proc. Natl. Acad. Sci. USA 92, 763-767.
Fauchère J. L., Quarendon P., and Kaetterer L. (1988) Estimating and representing hydrophobicity potential. J. Mol. Graphics 6, 203-206.
Haass C., Schlossmacher M. G., Hung A. Y., Vigo-Pelfrey C., Mellon A., Ostaszewski B. L., Lieberburg I., Koo E. H., Schenk D., and Teplow D. B. (1992) Amyloid beta-peptide is produced by cultured cells during normal metabolism. Nature 359, 322-325.
Halverson K., Fraser P. E., Kirschner D. A., and Lansbury P. T. J. (1990) Molecular determinants of amyloid deposition in Alzheimer's disease: conformational studies of synthetic beta-protein fragments, Biochemistry 29, 2639-2644.
Henderson R., Baldwin J. M., Ceska T. A., Zemlin F., Beckmann E., and Downing K. H. (1990) Model for the structure of bacteriorhodopsin based on high-resolution electron cryo-microscopy. J. Mol. Biol. 213, 899-929.
Holvoet P., Zhao Z., Vanloo B., Vos R., Deridder E., Dhoest A., Taveirne J., Brouwers E., Demarsin E., and Engelborghs Y. (1995) Phospholipid binding and lecithin-cholesterol acyltransferase activation properties of apolipoprotein A-I mutants. Biochemistry 34, 13334-13342.
Horth M., Lambrecht B., Khim M. C., Bex F., Thiriart C., Ruysschaert J. M., Burny A., and Brasseur R. (1991) Theoretical and functional analysis of the SIV fusion peptide. EMBO J. 10, 2747-2755.
Iwatsubo T., Odaka A., Suzuki N., Mizusawa H., Nukina N., and Ihara Y. (1994) Visualization of A beta 42(43) and A beta 40 in senile plaques with end-specific A beta monoclonals: evidence that an initially deposited species is A beta 42(43). Neuron 13, 45-53.
Jonas A., Steinmetz A., and Churgay L. (1993) The number of amphipathic alpha-helical segments of apolipoproteins A-I, E, and A-IV determines the size and functional properties of their reconstituted lipoprotein particles. J. Biol. Chem. 268, 1596-1602.
Kosik K. S. (1992) Alzheimer's disease: a cell biological perspective. Science 256, 780-783.
Lansbury P. T. J., Costa P. R., Griffiths J. M., Simon E. J., Auger M., Halverson K. J., Kocisko D. A., Hendsch Z. S., Ashburn T. T., and Spencer R. G. (1995) Structural model for the beta-amyloid fibril based on interstrand alignment of an antiparallel-sheet comprising a C-terminal peptide. Nat. Struct. Biol. 2, 990-998.
Li W. H., Tanimura M., Luo C. C., Datta S., and Chan L. (1988) The apolipoprotein multigene family: biosynthesis, structure, structure - function relationships, and evolution. J. Lipid Res. 29, 245-271.
Lins L. and Brasseur R. (1995) The hydrophobic effect in protein folding. FASEB J. 9, 535-540.
Lins L., Rosseneu M., Ruysschaert J. M., and Brasseur R. (1992) Mode of assembly of apolipoproteins with lipids - structural determinants of the complexes, in Structure and Function of Apolipoproteins (Rosseneu M., ed), pp. 251-268. CRC Press, Boca Raton, Florida.
Lins L., Brasseur R., De Pauw M., Van Biervliet J. P., Ruysschaert J. M., Rosseneu M., and Vanloo B. (1995) Helix - helix interactions in reconstituted high-density lipoproteins. Biochim. Biophys. Acta 1258, 10-18.
Lins L., Brasseur R., Malaisse W. J., Biesemans M., Verheyden P., and Willem R. (1996) Importance of the Hydrophobic energy: structural determination of a hypoglycemic drug of the meglitinide family by nuclear magnetic resonance and molecular modeling. Biochem. Pharmacol. 52, 1155-1168.
Mann D. M., Iwatsubo T., Ihara Y., Cairns N. J., Lantos P. L., Bogdanovic N., Lannfelt L., Winblad B., Maat-Schieman M. L., and Rossor M. N. (1996) Predominant deposition of amyloid-beta 42(43) in plaques in cases of Alzheimer's disease and hereditary cerebral hemorrhage associated with mutations in the amyloid precursor protein gene. Am. J. Pathol. 148, 1257-1266.
Martin I., Defrise-Quertain F., Mandieau V., Nielsen N. M., Saermark T., Burny A., Brasseur R., Ruysschaert J. M., and Vandenbranden M. (1991) Fusogenic activity of SIV (simian immunodeficiency virus) peptides located in the GP32 NH2 terminal domain. Biochem. Biophys. Res. Commun. 175, 872-879.
Martin I., Dubois M. C., Saermark T., and Ruysschaert J. M. (1992) Apolipoprotein A-1 interacts with the N-terminal fusogenic domains of SIV (simian immunodeficiency virus) GP32 and HIV (human immunodeficiency virus) GP41: implications in viral entry, Biochem. Biophys. Res. Commun. 186, 95-101.
Mattson M. P. (1995) Untangling the pathophysiochemistry of beta-amyloid. Nat. Struct. Biol. 2, 926-928.
Neider J. A. and Mead R. A. (1965) A simplex method for function minimization. Comput. J. 7, 303-313.
Pike C. J., Burdick D., Walencewicz A. J., Glabe C. G., and Cotman C. W. (1993) Neurodegeneration induced by beta-amyloid peptides in vitro: the role of peptide assembly state. J. Neurosci. 13, 1676-1687.
Pillot T., Goethals M., Vanloo B., Talussot C., Brasseur R., Vandekerckhove J., Rosseneu M., and Lins L. (1996) Fusogenic properties of the C-terminal domain of the Alzheimer beta-amyloid peptide. J. Biol. Chem. 271, 28757-28765.
Pillot T., Goethals M., Vanloo B., Lins L., Brasseur R., Vandekerckhove J., and Rosseneu M. (1997) Specific modulation of the fusogenic properties of the Alzheimer beta-amyloid peptide by apolipoprotein E isoforms. Eur. J. Biochem. 243, 650-659.
Pillot T., Goethals M., Najib J., Labeur C., Lins L., Chambaz J., Brasseur R., Vandekerckhove J., and Rosseneu M. (1999) β-Amyloid peptide interacts specifically with the carboxy-terminal domain of human apolipoprotein E: relevance to Alzheimer's disease. J. Neurochem. 72, 230-237.
Rosseneu M., Vanloo B., Lins L., Ruysschaert J. M., and Brasseur R. (1992) Analysis of the primary and secondary structure of apolipoproteins, in Structure and Function of Apolipoproteins (Rosseneu M., ed), pp. 159-183. CRC Press, Boca Raton, Florida.
Schmechel D. E., Saunders A. M., Strittmatter W. J., Crain B. J., Hulette C. M., Joo S. H., Pericak-Vance M. A., Goldgaber D., and Roses A. D. (1993) Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease. Proc. Natl. Acad. Sci. USA 90, 9649-9653.
Selkoe D. J. (1991) The molecular pathology of Alzheimer's disease. Neuron 6, 487-498.
Selkoe D. J. (1994) Amyloid beta-protein precursor: new clues to the genesis of Alzheimer's disease. Curr. Opin. Neurobiol. 4, 708-716.
Selkoe D. J. (1997) Alzheimer's disease: genotypes, phenotypes, and treatments. Science 275, 630-631.
Seubert P., Vigo-Pelfrey C., Esch F., Lee M., Dovey H., Davis D., Sinha S., Schlossmacher M., Whaley J., and Swindlehurst C. (1992) Isolation and quantification of soluble Alzheimer's beta-peptide from biological fluids. Nature 359, 325-327.
Shoji M., Golde T. E., Ghiso J., Cheung T. T., Estus S., Shaffer L. M., Cai X. D., McKay D. M., Tintner R., and Frangione B. (1992) Production of the Alzheimer amyloid beta protein by normal proteolytic processing. Science 258, 126-129.
Sisodia S. S. and Price D. L. (1995) Role of the beta-amyloid protein in Alzheimer's disease. FASEB J. 9, 366-370.
Sloop C. H., Dory L., and Roheim P. S. (1987) Interstitial fluid lipoproteins. J. Lipid Res. 28, 225-237.
Sparrow J. T., Sparrow D. A., Fernando G., Culwell A. R., Kovar M., and Gotto A. M. J. (1992) Apolipoprotein E: phospholipid binding studies with synthetic peptides from the carboxyl terminus. Biochemistry 31, 1065-1068.
Srinivas R. V., Birkedal B., Owens R. J., Anantharamaiah G. M., Segrest J. P., and Compans R. W. (1990) Antiviral effects of apolipoprotein A-I and its synthetic amphipathic peptide analogs. Virology 176, 48-57.
Strittmatter W. J., Saunders A. M., Schmechel D., Pericak-Vance M., Enghild J., Salvesen G. S., and Roses A. D. (1993a) Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc. Natl. Acad. Sci. USA 90, 1977-1981.
Strittmatter W. J., Weisgraber K. H., Huang D. Y., Dong L. M., Salvesen G. S., Pericak-Vance M., Schmechel D., Saunders A. M., Goldgaber D., and Roses A. D. (1993b) Binding of human apolipoprotein E to synthetic amyloid beta peptide: isoform-specific effects and implications for late-onset Alzheimer disease. Proc. Natl. Acad. Sci. USA 90, 8098-8102.
Suzuki N., Cheung T. T., Cai X. D., Odaka A., Otvos L. J., Eckman C., Golde T. E., and Younkin S. G. (1994) An increased percentage of long amyloid beta protein secreted by familial amyloid beta protein precursor (beta APP717) mutants. Science 264, 1336-1340.
Weisgraber K. H. (1990) Apolipoprotein E distribution among human plasma lipoproteins: role of the cysteine - arginine interchange at residue 112. J. Lipid Res. 31, 1503-1511.
Weisgraber K. H., Roses A. D., and Strittmatter W. J. (1994) The role of apolipoprotein E in the nervous system. Curr. Opin. Lipidol. 5, 110-116.
Westerlund J. A. and Weisgraber K. H. (1993) Discrete carboxyl-terminal segments of apolipoprotein E mediate lipoprotein association and protein oligomerization. J. Biol. Chem. 268, 15745-15750.
Wilson C., Wardell M. R., Weisgraber K. H., Mahley R. W., and Agard D. A. (1991) Three-dimensional structure of the LDL receptor-binding domain of human apolipoprotein E. Science 252, 1817-1822.
Wilson C., Mau T., Weisgraber K. H., Wardell M. R., Mahley R. W., and Agard D. A. (1994) Salt bridge relay triggers defective LDL receptor binding by a mutant apolipoprotein. Structure 2, 713-718.
Wisniewski T., Golabek A. A., Kida E., Wisniewski K. E., and Frangione B. (1995) Conformational mimicry in Alzheimer's disease. Role of apolipoproteins in amyloidogenesis. Am. J. Pathol. 147, 238-244.
Yankner B. A. (1996) Mechanisms of neuronal degeneration in Alzheimer's disease. Neuron 16, 921-932.
